(S1 (S (S (NP (NP (VBN Enforced) (NN expression)) (PP (IN of) (NP (NP (NN tissue) (NN inhibitor)) (PP (IN of) (NP (NN matrix) (NN metalloproteinase-3)))))) (VP (VP (VBZ affects) (NP (JJ functional) (NN capillary) (NN morphogenesis))) (CC and) (VP (VBZ inhibits) (NP (NP (NN tumor) (NN growth)) (PP (IN in) (NP (DT a) (JJ murine) (NN tumor) (NN model))))))) (. .)))
(S1 (S (S (NP (NP (NN Homeostasis)) (PP (IN of) (NP (DT the) (JJ extracellular) (NN matrix)))) (VP (VBZ is) (NP (NP (DT a) (JJ delicate) (NN balance)) (PP (IN between) (NP (NP (NN degradation)) (CC and) (NP (NN remodeling))))) (, ,) (S (NP (DT the) (NN balance)) (VP (VBG being) (VP (VBN maintained) (PP (IN by) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NP (VBN activated) (NN matrix) (NNS metalloproteinases)) (PRN (-LRB- -LRB-) (NP (NNS MMPs)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ specific) (NN tissue) (NNS inhibitors)) (PP (IN of) (NP (NN matrix) (NNS metalloproteinases)))) (PRN (-LRB- -LRB-) (NP (NNS TIMPs)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Up-regulation)) (PP (IN of) (NP (NN MMP) (NN activity))) (, ,) (VP (VBG favoring) (NP (NP (JJ proteolytic) (NN degradation)) (PP (IN of) (NP (NP (DT the) (NN basement) (NN membrane)) (CC and) (NP (JJ extracellular) (NN matrix)))))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN linked) (PP (TO to) (NP (NP (NP (NN tumor) (NN growth)) (CC and) (NP (NN metastasis))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ tumor-associated) (NN angiogenesis)))))))) (, ,) (IN whereas) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN MMP) (NN activity)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB restrict) (NP (DT these) (NNS processes)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN used) (NP (JJ retroviral-mediated) (NN gene) (NN delivery)) (S (VP (TO to) (VP (VB effect) (NP (NP (JJ sustained) (NN autocrine) (NN expression)) (PP (IN of) (NP (NN TIMP-3))) (PP (IN in) (NP (JJ murine) (NN neuroblastoma) (CC and) (NN melanoma) (NN tumor) (NNS cells))))) (SBAR (IN in) (NN order) (S (VP (TO to) (ADVP (RB further)) (VP (VB examine) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN TIMPs))) (S (VP (TO to) (VP (VB inhibit) (NP (NN angiogenesis)) (ADVP (FW in) (FW vivo))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Growth)) (PP (IN of) (NP (NP (DT both) (JJ histologic) (NNS types)) (PP (IN of) (NP (JJ gene-modified) (NN tumor) (NNS cells))))) (PP (IN in) (NP (NP (NP (JJ severe) (JJ combined) (NN immunodeficiency)) (PRN (-LRB- -LRB-) (NP (NN SCID)) (-RRB- -RRB-))) (NNS mice)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN restricted)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NNS controls)))))))) (. .)))
(S1 (S (S (ADVP (RB Grossly)) (, ,) (NP (DT these) (NNS tumors)) (VP (VP (VBD were) (ADJP (JJ small))) (CC and) (VP (VBD had) (NP (JJ few) (JJ feeding) (NNS vessels))))) (. .)))
(S1 (S (S (NP (JJ Histologic) (NN evaluation)) (VP (VBD revealed) (SBAR (IN that) (S (SBAR (IN although) (S (NP (NP (NNS tumors)) (VP (VBG overexpressing) (NP (NN TIMP-3)))) (VP (VBD had) (NP (NP (DT an) (VBN increased) (NN number)) (PP (IN of) (NP (JJ CD31-LRB-+-RRB-) (JJ endothelial) (NNS cells))))))) (, ,) (NP (DT these) (JJ endothelial) (NNS cells)) (VP (VBD had) (RB not) (VP (VBD formed) (NP (JJ functional) (NNS tubules)) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (VBN decreased) (NN vessel) (NN continuity)) (CC and) (NP (JJ minimal) (JJ pericyte) (NN recruitment))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VBN mediated) (, ,) (PP (IN in) (NP (NN part))) (, ,) (PP (IN by) (NP (NP (VBN decreased) (NN expression)) (PP (IN of) (NP (JJ vascular) (JJ endothelial) (PRN (-LRB- -LRB-) (NP (NN VE)) (-RRB- -RRB-)) (NN -cadherin))) (PP (IN by) (NP (NP (JJ endothelial) (NNS cells)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN TIMP-3)) (SBAR (IN as) (S (VP (VBN seen) (PP (CC both) (PP (IN in) (NP (DT an) (ADJP (FW in) (FW vitro)) (NN assay))) (CC and) (PP (IN in) (NP (JJ TIMP-3-overexpressing) (NNS tumors))))))))))))))))))))) (. .)))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS results)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NP (NN overexpression)) (PP (IN of) (NP (NN TIMP-3)))) (VP (MD can) (VP (VB inhibit) (NP (NP (NN angiogenesis)) (CC and) (NP (VBN associated) (NN tumor) (NN growth))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (JJ antiangiogenic) (NNS effects)) (PP (IN of) (NP (NN TIMP-3)))) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (VP (VBN mediated) (PP (IN through) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (JJ functional) (NN capillary) (NN morphogenesis))))))))))))))) (. .)))
